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ABSTRACT
Background: Congenital adrenal hyperplasia (CAH) due 21-hydroxylase deficiency (21-OHD) is
a common autosomal recessive disorder. It is caused by defects in the CYP21A2 gene.
Objective: Our aim was to determine the frequency of common gene mutations and to evalu-
ate genotype-phenotype correlations in Turkish 21-OHD patients.
Methods: Molecular analysis of the CYP21A2 gene was performed for the detection of the
eight most common point mutations [p.P30L, IVS2-13C>G (IVS-2), p.I172N, exon 6 mutation
cluster (p.I236N, p.V237E, p.M239K), p.V281L, p.Q318X, p.R356W, 8-bp-deletion], of large
deletion and conversion by southern blotting, allele specific semi-quantitative PCR/enzyme
restriction method and sequencing,  in 56 patients with 21-OHD, from 52 families.
Results: Disease-causing mutations were identified in 77 out of 91 alleles (84.6%) of the patients.
Mutations were found in 34 of 43 alleles (79.1%) in salt wasting (SW; n=26), 32 of 36 alleles
(88.8%) in simple virilizing (SV; n=24) and 11 of 12 alleles (91.6%) in non-classical (NC; n=6) form
of CAH.  The most frequent mutations were IVS-2 (22.0%), large conversion (14.3%), p.I172N
(9.9%) p.R356W (8.8%), and large deletion (6.6%). In the SW form, the most frequent genotypes
were homozygous for  IVS-2 (11.5%) and homozygous for large conversion of the gene (11.5%).
In the SV form, the most frequent genotype was homozygous for IVS-2 (20%), followed by com-
pound heterozygous for p.I172N/8-bp del (10%). Homozygous for  p.V281L (16.7%) was most
common in NC.  In most cases there was good correlation between genotype and phenotype. In
the SW and NC forms, genotypes of all the patients correlated with their phenotypes. 
Conclusions: This is the first comprehensive study on the molecular basis of CAH patients in the
Turkish population. Based on these results, we propose a modified screening strategy to facili-
tate molecular testing of CAH patients in our population. 
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INTRODUCTION
Congenital adrenal hyperplasia (CAH) is
a common autosomal recessive disorder that
is frequently caused by 21-hydroxylase defi-
ciency (21-OHD). Impaired 21-OH enzyme
activity leads to a deficiency in adrenal cor-
tisol and aldosterone production and to a
concomitant increase in androgen secretion.
CAH can be divided into classical and non-
classical forms. Clinically, classical CAH
occurs as the salt wasting (SW) form with a
complete lack of the 21-OH enzyme activity
or as the simple virilizing (SV) form with
partial impairment of 21-OH enzyme. In the
SW form, cortisol and aldosterone deficiency
may cause life-threatening hyponatremic
dehydration and shock. In classical 21-OHD,
prenatal androgen excess causes the devel-
opment of external genital ambiguity in
females. After birth, males and females with
the classical form exhibit progressive postna-
tal virilization. Reduced fertility and menstru-
al abnormalities in untreated women and
testicular adrenal rests in untreated men
have been observed.(1, 2, 3, 4, 5, 6)
Nonclassical 21-OHD (NC 21-OHD) results
from a mild deficiency of the 21-hydroxylase
enzyme with a reduced, but residual enzyme
activity. Female NC 21-OHD patients do not
demonstrate genital ambiguity at birth. Males
and females may manifest variable signs of
androgen excess at any phase of postnatal
development.(7)
Analysis of CAH incidence from 6.5 mil-
lion newborns screened in the general pop-
ulation worldwide, estimated the overall
incidence of 1:13,000-1:15,000 live births for
classical form of CAH.(8, 9) The prevalence
for classical forms in specific populations
has been reported as 1:10,000-23,000 in the
United States and Europe(10), 1:21,000 in
Japan(11) and 1:23,000 in New Zealand.(12)
In two populations, the Yupik Eskimos
(Alaska) and the people of La Reunion
(France), a high frequency of the classical
forms, 1:282 and 1:2141 respectively, has
been reported.(9) The frequency of the NC
form has been reported as 1:27 for
Ashkenazi Jews, 1:53 for Hispanics, 1:333 for
Italians and 1:1000 for other Caucasians.(7)
To date, over 100 mutations have been
described in the human CYP21A2 gene
which cause CAH. There are an increasing
number of reports concerning the genetics
of 21-OHD being published from various
countries worldwide.(1, 13, 14)Approximately
95% of all disease-causing mutations in
CYP21A2 gene are large deletions,  large
conversions or one of eight point mutations
[p.P30L, IVS2-13 C>G in intron 2 splice site
(IVS-2), 8bp deletion in exon 3, p.I172L,
Exon 6 cluster (p.I236N, p.V237E, p.M239K),
p.V281L, p.Q318X, p.R356W].  These com-
mon point mutations are due to unequal
crossing over between the pseudogene,
CYP21A1P and the active gene,
CYP21A2.(13, 14) Large deletions or large
conversions are typically associated with
classical SW, whereas the IVS-2 may be
associated with either the salt-wasting or
simple virilizing forms.  Specific missense
mutations associated with other forms of 21-
OHD include the simple virilizing Exon 4
I172N mutation and the non-classical muta-
tions, p.V281L, p.P30L, p.R339H and
p.P453S.(1, 3, 5, 15)Previously, several large
genetic screenings have been performed
with CAH families where the genotype-phe-
notype correlation was assessed with 80-90%
accuracy.(16, 17, 18, 19, 20, 21, 22)
We present here the screening results of
the most common CYP21A2 gene mutations
found in our Turkish patients with CAH and
an analysis of their genotype in relation to
phenotype.
SUBJECTS AND METHDOS
Subjects 
Fifty-two Turkish families with children
with 21-OHD from different areas in
Turkey participated in our study.  Four
families had two affected siblings.
Therefore, there were a total of 56 affected
patients studied.  Fifteen of the 52 familiesCYP21 Mutations in Congenital Adrenal Hyperplasia in Turkish Children
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studied demonstrated consanguinity. The
number of alleles was considered as 1 in
13 of the consanguineous families.
Heterozygous compound mutations were
found in 2 of the families. The number of
alleles was 2 in one of these families, while
only one mutant allele was found in the
second family. Therefore, the number of
alleles were 91 in total. There was no phe-
notypic variation in the four families with
affected siblings.
Blood samples were collected from the
affected and unaffected individuals of each
family. Informed consent was obtained in
all cases.
Phenotypic analysis
Clinical and hormonal evaluations were
used to categorize the patients with the SW,
SV, or NC forms of CAH.  It was found that
our study population consisted of 26
patients diagnosed as having  the SW form,
24 as having the SV form, and 6 as having
the NC form of CAH. The criteria used to
diagnose a SW form was either a SW crisis
in the newborn period or elevated plasma
renin activity (PRA) levels, hyponatremia
and hyperkalemia. Phenotypic features of
the SW and SV forms included growth fail-
ure in the first months of life, very early
pubarche, advanced bone age, acceleration
of growth, and ambiguous genitalia in the
affected female. The NC form presented
with normal external genitalia, hirsutism or
mild clitoromegaly in girls and, in both
sexes, by precocious pubarche.  
External genitalia was graded according
to Prader staging (23) in all females. ACTH
stimulation testing was done in some of the
patients to confirm their diagnoses. After
diagnosis was confirmed, hydrocortisone and
fludrocortisone replacement therapies were
started for SW patients and only hydrocorti-
sone for those affected with the SV and NC
forms of CAH.. Basic clinical and laboratory
characteristics of patients with different forms
Table 1: Clinical and laboratory findings of the patients with different forms of CAH
SW SV NC
Number of patients (n) 26 24 6
Age at diagnosis 
Mean ±SEM 31 ± 7 days 4.2 ± 0.6 yrs 9.0 ± 1.3 yrs
Range (1-180 days) (16 day-10.5 yrs) (5.8-15.3 yrs)
Median 22 days 4 yrs 8.3 yrs
Consanguinity n (%) 10 (38.5) 5 (20.8) 0.0
Prader staging (n) Stage 2 : 0 1 1
Stage 3 : 0 4 0
Stage 3-4 : 7 1 0
Stage 4 : 5 3 0
Stage 5 : 0 4 0
Normal: 12 11 Female:4,  Male:1
Karyotype 46 XX 14 13 5 
46 XY 12 11 1
17-OHP (baseline) (ng/ml)
Mean± SD 74.9 ± 118.8 39.8 ± 39.5 18.5 ± 11.2
Range 6.2-500 6.3-190 7.5-34
Androstenedione (baseline) (ng/ml)
Mean± SD 11.2 ± 6.5 9.9 ± 3.2 8.8 ± 8.5
Range 1.5-27 1.8-15 1.5-20
17-OHP=17 hydroxy progesterone; SW: salt wasting; SV: simple virilizing; NC: non-classical.of CAH are given in Table 1. Some patients
were re-evaluated  to confirm their diagnoses.
Hormonal investigations 
Serum adrenal precursors (17 hydroxy-
progesterone [17-OHP], testosterone, an-
drostenedione, dehydroepiandrostenedione-
sulphate) and PRA were measured by RIA
according to the procedure manual
(Diagnostic Systems Laboratories, Inc, Texas,
USA) at diagnosis and at follow-up.
Genetic analysis
DNA was extracted from peripheral
blood using a commercially available kit
(DNA Isolation Kit for Mammalian Blood,
Roche, Istanbul, Turkey). Genetic analysis
of 56 affected individuals was performed.
Seven analyses were completed at the
Mount Sinai School of Medicine in New
York and the other 49 were completed at
the Istanbul Faculty of Medicine in
Istanbul.  Allele-specific PCR was used to
screen the patients and families for the 8
most common mutations [p.P30L in exon 1,
IVS2-13C>G in intron 2, 8-bp deletion in
exon 3, p.I172N in exon 4, cluster mutation
in exon 6 (p.I236N, p.V237E, p.M239K),
p.V281L in exon 7, p.Q318X and p.R356W
in exon 8]. Southern blot analysis or semi
quantitative PCR/ enzyme digestion meth-
ods were performed to detect the large
deletions and conversions by the methods
reported previously by Tukel et al.(24)
Sequence analysis was performed on
patients with only one affected allele; the
p.R339H and p.P453S mutations were also
detected by sequence analysis. 
Statistical analysis
An SPSS-10 program was used for statis-
tical analyses. Comparison between the
means was done by nonparametric tests.
The results were expressed as an arithmetic
mean±SD. The relations between variables
were analyzed by Spearman’s correlation
test. The distribution of the mutations
among the three clinical types were com-
pared using chi-square tests, p≤0.05 was
considered statistically significant.
RESULTS
Clinical and laboratory findings of these
Turkish patients with CAH who were
screened for genetic mutations are summa-
rized in Table 1. Age at diagnosis of the SW
patients was lower than the SV and NC
patients (p<0.001). There was no significant
difference in the Prader stages of the SW and
the SV patients (p=0.1). 
Frequency of consanguinity was 32.0% in
all patients with classical CAH: 38.5% in the SW
population, and 20.8% in the SV population.
17-OHP and androstenedione levels were
found to be higher in those with SW than in
those with SV, but the difference was not sig-
nificant (p=0.743 and p=0.545, respectively).
At the time of diagnosis, there were correla-
tions between  age and androstenedione lev-
els (r=0.584, p=0.009), 17-OHP levels and
birth weight (r=0.540, p=0.038), androstene-
dione and testosterone (r=0.892, p=0.003) in
the SV patients. There were no such correla-
tions in the SW patients.
The disease-causing mutations were
identified in 77 of 91 unrelated alleles
(84.6%) for the three forms of CAH:  34 of 43
alleles (79.1%) in SW, 32 of 36 alleles
(88.8%) in SV and 11 of 12 alleles (91.6%) in
NC. Mutations of all three forms of CAH are
summarized in Tables 2 and 3, and the
mutation frequencies of affected alleles in 52
unrelated patients are shown in Table 3.
Among the 91 unrelated alleles, distribution
of the most frequent mutations were IVS-2,
large conversion of the CYP21 gene,
p.I172N, p.R356W, and large deletion of the
CYP21 gene, as seen in  Table 3. 
In the SW patients, the most frequent
mutation observed was IVS-2, followed by
large conversion of the gene, p.R356W, large
gene deletion, and p.Q318X. The most fre-
quent genotypes in this patient population
were homozygous for IVS-2 and homozy-
gous for  large conversion of the gene. One
Baﬂ F., et al.
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Table 2: Genotype and phenotype of all patients with CAH 
Patient Consanguinity Alleles Genotype Phenotype Karyotype Prader Baseline
n mutations 46, stage 17-OHP  
(ng/ml)
1 - 2 p.R356W/ND SW XX 3-4 -
2§ + 1 p.R356W/p.R356W SW XX 3-4 31.2
3 - 2 IVS-2/p.R356W SW XY N (M) 163
4§ + 1 conv/conv SW XX 3-4 7.5
5§ + 1 del/del SW XY N (M) 36.5
6§ + 1 p.Q318X/p.Q318X SW XY N (M) 16.5
7§ + 1 p.Q318X/p.Q318X SW XY N (M) 21.8
8§ - 2 conv/ND SW XX 4 -
9§ + 1 del/del SW XX 3-4 30.9
10§ + 1 conv/conv SW XX 4 -
11 + 1 IVS-2/IVS-2 SW XY N (M) 20.0
12§ - 2 IVS-2/ND SW XX 3-4 33.0
13§ - 2 conv/conv SW XX 3-4 -
14 - 2 conv/ND SW XX 3-4 -
15§ - 2 conv/p.R356W SW XY N (M) 50.0
16 - 2 conv/ND SW XY N (M) 38.7
17 - 2 p.R356W/IVS-2 SW XX 4 23.0
18§ - 2 p.Q318X/ND SW XX 3 31.8
19§ - 2 del/ND SW XX 4 ?
20 + 2 IVS-2/del SW XY N (M) 6.2
21 - 2 ND/ND SW XY N (M) 20.0
22§ + 1 IVS-2/IVS-2 SW XY N (M) 168
23 - 2 IVS-2/8-bp del SW XX 4 34.5
24 - 2 IVS-2/conv SW XX 3 51.0
25 - 2 IVS-2/IVS-2 SW XY N (M) 250
26 - 2 p.[[R356W]+[V281L] SW XY N  (M) 14.5
(+)I172N]
27 - 2 ND/ND SV XY N (M) 31.6
28* a - 2 E-6/p.V281L SV XX 3 ?
b E-6/p.V281L SV XY N  (M) 84.0
29*§ a - 2 p.I172N/8-bp del SV XY N (M) 41.4
b p.I172N/8-bp del SV XY N (M) 82.8
30 - 2 del/p.R339H SV XY N (M) 25.0
31§ + 1 IVS-2/IVS-2 SV XX 5 55.0
32 - 2 conv/conv SV XY N (M) 17.3
33§ - 2 p.I172N/p.I172N SV XX 2 37.1
34* a - 2 p.I172N/8-bp del SV XX 5 20.0
b p.I172N/ 8-bp del SV XY N (M) 20.0
35 + 1 IVS-2/IVS-2 SV XX 3-4 27.5
36§ - 2 E-6/p.I172N SV XX 3 190
37§ - 2 IVS-2/p.P453S SV XY N (M) 6.3
38§ - 2 IVS-2/IVS-2 SV XY N (M) 34.2
39 + 1 p.I172N/p.I172N SV XX 3 55.0
40* a + 1 p.R356W/p.R356W SV XY N (M) 32.1
b p.R356W/p.R356W SV XX 4 36.1Baﬂ F., et al.
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of the SW patients had a complex allele
p.[[R356W]+[V281L](+)I172N]. His mother
was a carrier of the p.R356W and his father
was a carrier of the V281L mutation, and
I172N had occurred de novo.
In the SV patients, the most frequent
mutation observed was IVS-2, followed by
p.I172N, large conversion of the gene and
p.R356W as seen in Table 3. The most fre-
quent genotype was homozygous for IVS-2,
followed by compound heterozygous for
p.I172N/8-bp del. The p.I172N, cluster exon
6 (p.I236N, p.V237E, p.M239K), p.V281L,
p.P453S, and p.R339H mutations were pres-
ent among the SV patients, but absent in
patients with the SW form. The p.Q318X
mutation which was one of the most frequent
mutations in the SW patients was not found
in the SV or NC patient population. The IVS2-
mutation showed a similar prevalence in both
the SW and SV forms as seen  in Table 3. 
In the NC population, the most frequent
mutation observed was p.V281L. Other
mutations were IVS-2, del8bp, large gene
deletion, p.I172N , p.R453S and p.R339H as
seen in Table 3. In the NC form, the most
frequent genotype was homozygous for
p.V281L (16.7%). There were 4 compound
heterozygous mutations in the NC cases:
gene deletion/p.R339H, IVS-2/p.P453S,
p.I172N/p.V281L, and p.V281L/8-bpdel as
seen  in Table 2. 
In patients with the classical form of
CAH, the frequency of compound heterozy-
gous mutations was found to be 34.8%
(16/46): 26.9% (7/26) in the SW form, and
45% (9/20) in the SV form.  One of the SW
patients showed a compound heterozygous
mutation (IVS-2/large gene deletion), despite
his parents being consanguineous.  The fre-
quency of homozygous mutations was found
to be 41.3% (19/46) in all classical CAH
patients: 42.3% (11/26) in the SW form, and
40.0% (8/20) in the SV form.  The frequency
of detecting only one mutation in one allele
was observed to be 19.6% (9/46) in all clas-
sical CAH patients: 26.9% (7/26) in the SW
form, 10.0% (2/20) in the SV form.  For the
Table 2: continued
Patient Consanguinity Alleles Genotype Phenotype Karyotype Prader Baseline
n mutations 46, stage 17-OHP  
(ng/ml)
41§ - 2 p.I172N/p.R356W SV XX 3 14.9
42§ - 2 IVS-2/IVS-2 SV XX 5 26.6
43 - 2 IVS-2/ND SV XX 5 20.0
44 - 2 conv/p.I172N SV XX 4 7.0
45 + 2 p.V281L/ND SV XX 4 12.0
46 - 2 conv/IVS-2 SV XY N (M) ?
47§ - 2 IVS-2/p.P453S NC XX 1 24.8
48§ -   2 del/p.R339H NC XX N (F) ?
49 - 2 p.I172N/p.V281L NC XX N (F) 7.5
50 - 2 p.V281L/8-bp del NC XX N (F) 17.7
51 - 2 p.V281L/ND NC XX N (F) 8.5
52 - 2 p.V281L/p.V281L NC XY N (M) 34.0
ND: not detected; N: normal;  F: female; M: male; 17-OHP=17 hydroxy progesterone; SW: salt wasting; SV: simple virilizing; NC:
non-classical
conv: 5’ end large conversion, del: large deletion, 8-bp del: 8-bp deletion
IVS-2: intron 2 splice site mutation (IVS2-13C>G )
E-6: Exon 6 cluster mutations (p.I236 N, p.V237E, p.M239K)
*a, b: affected siblings 
§: Previously reported patients by Tukel T, et al (24)CYP21 Mutations in Congenital Adrenal Hyperplasia in Turkish Children
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NC population, the frequency of detecting
only one mutation in one allele was 16.6%
(1/6). There were no mutations found in
both alleles in 4.3% (2/46) of all classical
CAH patients: 3.8% (1/26) in the SW form,
and 5% (1/20) in the SV form (Table 2).  
In most 21-OHD cases there is good cor-
relation between genotype and phenotype.
In the SW and NC forms, genotypes of all
participating patients correlated with their
phenotypes. However, in the SV form, 5 out
of 24 patients had genotypes that would pre-
dict the NC form. These 5 patients had a
severe mutation on 1 allele and a mild muta-
tion on the other (Table 2, patients 28 a, 28
b, 30, 37, 45). In addition, two sibs with the
SV form had a severe mutation on both alle-
les (Table 2, patients 40 a and 40 b) that
would predict the SW form.
DISCUSSION
We have identified the disease-caus-
ing mutations on 77 of 91 (84.6%) alleles
using the described screening methods for
the most common mutations. The muta-
tions were found on 34 of 43 alleles
(79.1%) in SW, 32 of 36 alleles (88.8%) in
SV and 11 of 12 alleles (91.6%) in NC. In
our study, the frequency of undetectable
mutations was 15.4%. This rate varied
between 0 and 26.7% in other studies.(18,
20, 22, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, 40, 41)The incidence of
CYP21A2 gene mutations in 21-OHD has
been extensively studied. Results of
CYP21A2 gene mutations in different pop-
ulations are summarized in Table 4. 
The present study shows that the fre-
quencies of the 8 most common mutations
are similar to results obtained from
Western European and American popula-
tions (Table 4).(17, 19, 20, 25, 29, 31)In our
study, the frequency of p.Q318X was
slightly lower as compared to the Italian
population.(29) The frequency of p.V281L
was higher those reported for Netherlands
(31) and American populations.(25) The fre-
Table 3: Distribution of mutations obtained in unrelated Turkish patients with CAH due to 21-OHD 
Mutations Classical form Total Total
SW SV NC frequency 
n(%) n(%) n(%) n (%) 
IVS-2 10 (23.3) 9 (25.0) 1 (8.3) 20 22.0
large conversion  9 (20.9)  4 (11.4)  0 (0.0) 13 14.3
p.R356W 6 (14.0) 2 (5.5) 0 (0.0) 8 8.8
large deletion 4 (9.3) 1 (2.8) 1 (8.3) 6 6.6
8-bp deletion 1 (2.3) 2 (5.5)  1 (8.3) 4 4.4
p.Q 318X 3 (7.0) 0 (0.0) 0 (0.0) 3 3.3
p.I172N 0 (0.0) 8 (22.2) 1 (8.3) 9 9.9
p.P453S 0 (0.0) 1 (2.8) 1 (8.3) 2 2.2
p.R339H 0 (0.0) 1 (2.8) 1 (8.3) 2 2.2 
E-6 0 (0.0) 2 (5.5) 0 (0.0) 2 2.2
p.P30L 0 (0.0) 0 (0.0) 0 (0.0) 0 0.0
p.V281L 0 (0.0) 2 (5.5) 5 (41.7) 7 7.6
p.[ V281L](+)I172N]* 1 (2.3) 0 (0.0) 0 (0.0) 1 1.1
ND 9 (20.9) 4 (11.2) 1 (8.3) 14 15.4
Total detected 34 (79.1) 32 (88.8) 11 (91.6) 77 84.6 
Total 43 (100)  36 (100) 12 (100) 91 100.0
ND : not detected; IVS-2: intron 2 splice site mutation (IVS2-13C>G); SW: salt wasting; SV: simple virilizing; NC: non-classical
E-6: Exon 6 cluster mutations (I236N, V237E, M239K)
*a  complex allelequency of 8-bp del was found to be lower
than the American figures (Table 4).(25)
Additionally, some differences were
observed in the distribution of these com-
mon mutations in Turkish patients when
compared to Eastern European, Latin,
Asian, Iranian, and Tunisian populations.
The frequency of the IVS-2 mutation in
classical CAH patients was high in Romania
(43.9%) (33) and Hungary (41.3%) (42), in
comparison to 24.0 % in Turkish patients
with classical CAH.  The most frequent
mutation in the Tunisian CAH population
was found to be p.Q318X (35.3%), in con-
trast to 0.5-13.8% described in another
report.(39) In our study, the p.Q318X
mutation was only found in those patients
with the SW form. Also, we found that the
mutation frequency of p.Q318X in the
Turkish patients (3.3%) to be  lower than in
the Tunisian population.(39)
The frequencies of p.R356W and 8-bp del
mutations were found to be 10.1% and 3.8%,
respectively, in our Turkish patients with clas-
sical CAH. This differed from the figures for
Iranian patients with classical CAH who
demonstrated no p.R356W mutations as well
as a higher frequency of the 8-bp del (10%)
mutation.(40) Unlike some populations, the
p.P30L mutation was not detected in Turkish
patients with classical or non classical CAH. 
The distribution of mutations in a newly
Table 4: Distribution of mutations in unrelated Turkish patients affected by CAH, 21-OHD, in comparison with other populations
Total Large Large 8-bp
Alleles del conv IVS-2 p.I172N p.R356W del p.Q318X p.P30L E-6 p.V281L ND
Country n % % % % % % % % % % % Reference
Turkey 91 8.8 14.3 22.0 9.9 8.8 4.4 3.3 0 2.2 7.6 15.4 present
France 182 18 7 20 4 NT 7 NT 11 15 16 22
USA 334 22.6* 35.5 10.7 5 10 5 2 5 25
UK 284 45* 30.3 7 9.8 0 0 0 0 0 7.8 26
Sweden 186 ? ? 30 21 4.5 1 3.5 1 7 ? 18
Finland 102 34 6 12 29 2 10 3 4 27
Spain 120 15.8 12.5 30 4.16** 10 ** 9.2 0.83*** *** 14.2 28
Italy 146 26* 20 6 8 3 12 11 14 29
Italy 50 8* 56 6 4 2 4 4 6 2 30
(Southern)
Germany 310 20.3 7.1 30.3 19.7 4.5 1.6 4.8 2.6 1 2.9 1.3 20
Netherlands 370 31.9* 28.1 12.4 8.4 4.3 3.5 0.3 3.0 2.2 0 31
Greece 222 13.5* 29.3 13.5 0.45 2.25 8.6 11.3 10.8 6.3 32
Romania 66 16.7* 43.9 12.1† 1.5 † 7.6 33
Japan 102 18* 29 13 13 0 0 0 5 1 26 34
Argentina‡ 72 18* 18 15.3 5.5 2.7 13.8 0 NT 26.7 35
Argentina 73 4.2* 9.6 5.5 9.6 8.2 8.2 0 2.7 24.7 21.9 36
Brazil 228 5 7 20.6 14 7 1.3 5.7 2.2 0.9 18 20 37
Mexico 94 1 47 11.7 7.4 2.1 4.3 8.5 0 8.5 24 38
Tunis 102 19.6 17.6 10.8 2.9 35.3 5.9 39
Iran‡ 60 25 15 11.7 10 6.7 1.7 6.7 17 40
Turkey 200 17 28.5 4 3.5 3 11.5 1 1 3.5 22 41
conv: gene conversion, del: deletion, IVS-2: intron 2 splice site mutation (IVS2-13C>G)
E-6; Exon 6 cluster mutations (p.I236 N, p.V237E, p.M239K), NT; Not tested, ND; Not detected
* large gene rearrangement (large deletion and large gene conversion)
**p. I172N and 8-bp del, **** p.P30L and E-6 mutations
†p.I172N, p.P30L, IVS-2 and 8-bp del, ‡ This study evaluated only classical forms.
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reported study from Turkey revealed muta-
tions in 78% patients with slight differences in
the frequency of some mutations as summa-
rized in Table 4. There were patients from dif-
ferent areas of Turkey except for the Marmara
region in that study, (41) whereas our study
included patients from all parts of Turkey.
Recently, important variations in allelic
mutation frequencies were demonstrated in
different ethnic groups in a large study by
Wilson et al.(16) A high prevalence of the
following mutations were found in the
respective ethnic populations: The V281L
mutation in Ashkenazi Jews, an IVS-2 muta-
tion in Iranians and Yupik Eskimos of
Western Alaska, a large gene deletion in
Anglo-Saxons, a p.R356W mutation in
Croatians; and a p.Q318X mutation in East
Indians.(16)
There is a wide spectrum of severity of
the disease with a good correlation between
genotype and clinical phenotype in 21-
OHD, with few exceptions. In Caucasian
populations, deletions and gene conversions
are associated with the SW form, whereas
the IVS-2 mutation may be associated either
with the SW or SV form. V281L mutation is
found to be common in NC CAH.(7, 17, 18,
19, 20, 22, 14, 26, 29, 31)
In our study most cases demonstrated
good correlations between genotypes and
phenotypes. In the SW and NC forms, geno-
types of all the patients when detected cor-
related with their phenotypes. However, in
the SV form non-concordance of
genotype/phenotype was found in 5 out of
24 patients. These patients’ genotypes
(p.V281L or p.R399H or p.P453S on one
allele) predicted the NC form. In addition,
two sibs diagnosed with the SV form carried
the homozygous p.R356W mutations which
predict the SW form. In some studies, phe-
notypic variation has been detected.
However, the phenotypic variations do not
always correlate with allelic variation. For
instance, patients who were homozygous for
IVS-2 mutation were found to have either
the SW or SV phenotype.(25, 43, 44, 45)The
I172N mutation is usually associated with
the SV form,(17, 18, 19) although patients
with the SW form have been reported to
have the p.I172N/deletion genotype.(17, 25)
Phenotypic variance may be present in sib-
lings, which suggests a role for modifiers of
21-OHD transcription, translation, and
action.(46)
Wilson et al (16) observed a non concor-
dant genotype/phenotype correlation when
at least one IVS-2 mutation was present. It
was suggested that the genotype/phenotype
non-correlation in patients with the IVS-2
mutation might result from the variable
splicing of this mutation. The variable
expression could be due to variation in RNA
splicing factors.(16)
In our study, a severe mutation (large
gene deletion or IVS-2) was found on one
allele in two compound heterozygote indi-
viduals described as having non-classical
CAH. These patients are at 25% risk for hav-
ing a child with classical 21-OHD if his/her
partner is also a carrier of a classical muta-
tion. Prenatal treatment and diagnosis
should be offered if the partner carries a
classical mutation.
The variability in the phenotypic
expression of NC 21-OHD has been deter-
mined in previous studies. Compound het-
erozygosity with one mild and one severe
mutation can lead to more severe clinical
findings than carrying two mild mutations.
The existence of a subgroup with com-
pound heterozygosity for one mild and one
severe mutation may have important impli-
cations for future genetic and prenatal
counseling.(14, 47) One of our patients
whose parents were consanguineous
demonstrated compound heterozygosity.
This is unusual since the offspring of con-
sanguineous parents usually have homozy-
gous mutations.
The compound heterozygosity in our
study (34.8%) was  highly  similar to
Tunisian (39)and German (20)patients with
21-OHD (17.6% and 72,25%, respectively),
despite the high frequency of consanguinity.However, compound heterozygosity in
another study from Turkey (41) was found
to be lower (7%) than in our study in the
presence of higher rate of consanguinity. 
Some alleles can carry more than one
mutation.(20, 31, 32, 33, 38, 39)In our study,
one of the SW patients had a complex allele
comprised of p.[[R356W]+[V281L]+[I172N]].
His mother was a heterozygous carrier for
the p.R356W and his father was a heterozy-
gous carrier for the p.V281L mutation.
Neither parent had the p.I172N mutation.
This mutation could have occurred as a de
novo mutation originating in only one germ
cell or due to gonadal mosaicism. 
In 10 of our patients (6 SW, 2 SV and 1
NC), one allele was found to be affected
while the other allele did not have any muta-
tion. Wilson et al
25 also reported a family in
which only one mutant allele was found.
CYP21A2 gene sequencing did not show any
other genetic alterations, although  other
regions were tested for mutations (e.g. pro-
moter regions, intronic region) on the second
allele. Krone et al (20) also reported two
patients in which only one affected allele
was detected, although clinical and hormon-
al findings of these patients were compatible
with 21-OHD. Other studies have detected
mutations in the CYP21 promoter, (48) and
transcriptional regulatory regions.(49)
Recently, Escobar-Morreale et al (50)sug-
gested that the cutoff value for basal 17 OHP
for the detection of NC CAH should be 1.7
ng/ml instead of the currently recommended
2 ng/ml as the upper limit of the normal
ranges in women. However, basal 17 OHP
levels in our patients with NC 21-OHD were
found higher than the recommended cutoff
levels. Molecular diagnosis could also be
useful to resolve the problems of false neg-
ative or positive results which might occur
during biochemical diagnosis in the new-
born.  Identification of the genotype could
be a guide in planning a strategy for prena-
tal treatment and for newborn screening
programmes. The relationship between
genotype and phenotype may also be of
value in evaluating  response to treat-
ment.(51)
In conclusion, this study presents the
results of the first genotype-phenotype molec-
ular study of 21-OHD in Turkish patients, the
initial findings of which were reported previ-
ously.(24) The frequencies of common muta-
tions were similar to Western European and
American populations. With the exception of a
few cases, a genotype-phenotype correlation
has been observed in this group of patients.
Based on these finding, screening policies will
be instituted for the Turkish population. 
We believe these data will be useful in
giving enhanced patient care, in offering
genetic counseling, and also in prenatal
diagnosis and, treatment.  They may also
prove to be useful in the detectipn of carri-
ers.  Furthermore, the diagnosis of CAH will
be made more accurately when based on
the results of genetic testing. 
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